Michael J. Manyak - Concepedia

Author

Michael J. Manyak

Also Known As

M J Manyak, M. J. Manyak, M. Manyak, M.J. MANYAK, M.J. Manyak, MICHAEL J MANYAK, MICHAEL J. MANYAK, MICHAEL MANYAK, Manyak, Michael J, Michael J Manyak

132

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

George Washington University GlaxoSmithKline (United States)Washington University Medical Center The University of Texas Southwestern Medical Center GlaxoSmithKline (Spain)

About

Michael J. Manyak is an author at George Washington University specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	781
2	Engineering	3	3	116
3	Health Sciences	1	1	21
4	Natural Sciences	1	1	32
5	Allergy	1	1	21

Michael J. Manyak

Publications

Citations

H-Index

Page 1

	Year	Citations
Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. F A Attiga, Patricia M. Fernández, Ashani T. Weeraratna, PubMed UrologyChemoprevention StrategyMedicineArachidonic AcidMatrix Metalloproteinases	2000	307
( <sup>111</sup> ) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY Daniel Kahn, Richard D. Williams, Michael J. Manyak, The Journal of Urology	1998	172
Evaluation of Superficial Bladder Transitional-Cell Carcinoma by Optical Coherence Tomography Michael J. Manyak, Natalia D. Gladkova, John H. Makari, Journal of Endourology	2005	116
Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer Michael J. Manyak, George H. Hinkle, John O. Olsen, Urology Definitive TherapyUrologyGenitourinary CancerMedicineIndium-111-capromab Pendetide	1999	111
Comparison of clinical staging algorithms and111Indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients Thomas J. Polascik, Michael J. Manyak, Michael K. Haseman, Cancer	1999	105
Efficacy and safety of a fixed‐dose combination of dutasteride and tamsulosin treatment ( <scp>D</scp> uodart <sup>®</sup> ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment‐naïve men with moderately symptomatic benign prostatic hyperplasia: 2‐year <scp>CONDUCT</scp> study results Claus G. Roehrborn, Igor Oyarzabal Perez, Erik P.M. Roos, British Journal of Urology	2015	90
A comparison of urinary nuclear matrix protein‐22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer:the prognostic value of false‐positive results Vassilis Poulakis, U. Witzsch, Rachelle de Vries, British Journal of Urology	2001	83
Computer recognition of cancer in the urinary bladder using optical coherence tomography and texture analysis Colleen A. Lingley-Papadopoulos, Murray H. Loew, Michael J. Manyak, Journal of Biomedical Optics EngineeringDigital PathologyPathologyDiagnostic ImagingComputer Recognition	2008	73
Practice Trends in the Diagnosis and Management of Benign Prostatic Hyperplasia in the United States William F. Gee, Logan Holtgrewe, Peter C. Albertsen, The Journal of Urology	1995	71
Photodynamic Therapy for Refractory Superficial Bladder Cancer: Long-Term Clinical Outcomes of Single Treatment Using Intravesical Diffusion Medium Michael J. Manyak, Kenneth Ogan Journal of Endourology	2003	70

Page 1